<DOC>
	<DOCNO>NCT01538472</DOCNO>
	<brief_summary>The goal clinical research study see high-dose chemotherapy ( BEAM ) rituximab , give together new drug 90Y Zevalin , follow transplant blood marrow stem cell safe . Another goal learn treatment help decrease chance cancer come back .</brief_summary>
	<brief_title>Y Zevalin BEAM Autologous Stem Cell Transplantation ( ASCT ) Lymphoma</brief_title>
	<detailed_description>BEAM chemotherapy standard treatment lymphoma . BEAM combination chemotherapy drug ( carmustine , cytarabine , etoposide , melphalan ) . Rituximab antibody make human mouse protein . It react certain molecule surface lymphoma cell help body 's immune system destroy lymphoma cell . 90Y Zevalin also antibody make mouse protein . However , particle radiation attach . 90Y Zevalin work attach lymphoma cell , radiation particle destroy lymphoma cell . For study , receive rituximab vein follow dose 111In Zevalin vein ( 15 minute ) . 111In Zevalin different study drug ( 90Y Zevalin ) . 111In Zevalin different type radioactive particle attach . This particle kill lymphoma cell , `` see '' inside body use special camera ( like x-ray ) . 111In Zevalin use predict fast study drug travel body long drug stay body . Doctors need able see much drug go tumor much go normal organ determine safe give 90Y Zevalin outpatient basis . A scan do soon 111In Zevalin give 2-24 hour later . Scans also do 2-3 day later . If radiation 111In Zevalin threat normal organ bone marrow , may receive 90Y Zevalin . Seven ( 7 ) day 111In Zevalin injection , receive second dose rituximab follow dose 90Y Zevalin vein ( 15 minute ) . Seven ( 7 ) day 90Y Zevalin injection , receive BEAM combination chemotherapy . You receive carmustine ( 2 hour ) Day 1 chemotherapy . You receive cytarabine ( 2 hour ) follow etoposide ( 4 hour ) twice day Days 2 5 . On Day 6 , receive melphalan ( 20 minute ) . A catheter ( small flexible tube ) place large vein chest chemotherapy drug give easily . This call central venous catheter . All chemotherapy drug give central venous catheter . One day finish chemotherapy , stem cell collect earlier give back vein 30 minute . Starting day , receive treatment G-CSF injection skin day . Treatment G-CSF continue blood count reach certain level . You receive rituximab vein ( 6 8 hour ) day transplant 1-week later . Blood test ( 1-2 tablespoon ) , urine test , bone marrow collection , x-rays do need track effect transplant . You transfusion blood platelet need . Blood test ( 1 tablespoon ) do day hospital . Blood test ( 1-2 tablespoon ) , urine test , bone marrow collection , x-ray , CT scan , PET scan do every 3 month 1 year every 6 month 5 year check status disease . You ask give extra blood sample ( around 1 tablespoon ) study entry upon return visit M. D. Anderson . These sample use test certain molecule blood ( HAMA soluble CD20 ) check level rituximab blood . Treatment give hospital University Texas ( UT ) MD Anderson . You need stay hospital 3 4 week . You stay Houston area 2 4 week transplant . After , need return Houston time time blood test , urine test , exams . This investigational study . This investigational study . 90Y-Zevalin approved FDA relapse refractory lymphoma . Its use trial , however , investigational . All drug use study FDA approve commercially available . Up 60 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Relapsed CD20positive Bcell nonHodgkin 's lymphoma ( NHL ) ( demonstrate lymph node bone marrow ) , chemosensitive ( least Partial Remission ( PR ) ) . 2 . No anticancer therapy start within three week , prior study initiation , fully recover toxicity associate prior surgery , radiation treatment , chemotherapy , immunotherapy . No prior Rituximab within three week start therapy . 3 . No prior radioimmunoconjugate therapy . 4 . If patient prior radiation , involve 25 % bone marrow . 5 . An IRBapproved sign informed consent . 6 . Age : 18 65 year age . 7 . Acceptable hematologic status within two week prior patient registration , include : Absolute neutrophil count ( [ segment neutrophil + band ] * total white blood count ( WBC ) ) &gt; 1,500/mm3 . Platelet count &gt; 100,000/mm3 . 8 . Patients determine &lt; 10 % bone marrow involvement lymphoma within four week stem cell collection define bilateral aspirate biopsy . 9 . Prestudy performance status 0 , 1 , 2 accord World Health Organization ( WHO ) . 10 . Female patient include must pregnant lactating . 11 . Men woman reproductive potential follow acceptable birth control method ( determine treat physician , however abstinence acceptable method ) . 12 . Patients previously treat Phase II drug include longterm toxicity expect , patient drug four week significant post treatment toxicity observe 13 . Patients least 4 * 106 CD34+/kg peripheral stem cell collect . Whenever possible , 1 2 * 106 CD34+/kg , first 10 patient hold 1 year case graft failure . If graft failure occur first 10 patient , backup cell require subsequent patient . 1 . Patients impair bone marrow reserve , indicate one following : Prior myeloablative therapy autologous bone marrow transplantation ( ABMT ) peripheral blood stem cell ( PBSC ) rescue Platelet count &lt; 100,000 cells/mm3 Hypocellular bone marrow Marked reduction bone marrow precursor one cell line ( granulocytic , megakaryocytic , erythroid ) History fail stem cell collection &gt; 4*106 CD34+/kg 2 . Prior radioimmunotherapy . 3 . Presence central nervous system ( CNS ) lymphoma . 4 . Patients chronic lymphocytic lymphoma . 5 . Patients human immunodeficiency virus ( HIV ) acquire immune deficiency syndrome ( AIDS ) relate lymphoma . 6 . Patients abnormal liver function : total bilirubin &gt; 1.5 mg/dl 7 . Patients abnormal renal function : serum creatinine &gt; 1.6 mg/dl 8 . Patients receive prior external beam radiation therapy &gt; 25 % active bone marrow ( involved field regional ) . 9 . Serious nonmalignant disease infection , opinion investigator and/or sponsor , would compromise protocol objective . 10 . Corrected carbon monoxide diffusion lung ( DLCO ) &lt; 50 % forced expiratory volume 1 second ( FEV1 ) force vital capacity ( FVC ) &lt; 50 % predict . 11 . Cardiac ejection fraction ( EF ) &lt; 50 % 2D Echogram . 12 . Pleural effusion . 13 . Prior radiation lung . 14 . Abnormal cytogenetics , filter situ hybridization ( FISH ) ( 5 , 7 , 11q23 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Relapse B-cell CD20+ non-Hodgkin 's lymphoma</keyword>
	<keyword>High-dose BEAM chemotherapy</keyword>
	<keyword>Y Zevalin</keyword>
	<keyword>In Zevalin</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>BCNU</keyword>
	<keyword>1,3-bis ( 2-chloroethyl ) -1-nitrosourea bis-chloronitrosourea</keyword>
	<keyword>Carmustine</keyword>
	<keyword>BiCNU</keyword>
	<keyword>VP-16</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Stem cell infusion</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
</DOC>